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ABSTRACT 
A phytomedicine, or phytopharmacutical, is a complex mixture derived from plant sources that is used as a medicine or drug. The Ministry of 
Health has begun the standardization of the names of all phytopharmaceutical preparations. The development of phytopharmaceutical 
products, which might partially substitute some of the conventional medications demanding imported raw materials, and which could be 
produced by pharmaceutical industries based in developing countries through joint projects. Highest demands are made on clinically proven 
phyto-pharmaceuticals. Their effect and safety have to be verified in randomized, double-blind, (placebo)-controlled clinical trials. They are 
developed and scientifically evaluated in the same way as conventional medicinal products. Globally, herbal medicine has been considered an 
important alternative to modern allopathic medicine. While they have become very popular, only select herbs have been scientifically evaluated 
for their potential in medical treatment. The new drug Veregen (Polyphenon E) Ointment is the first prescription botanical (herbal) drug 
approved by the U.S. FDA under the “new” drug amendments of 1962 that required drugs to be proven safe and effective prior to being 
marketed in the U.S. Because of the unique health benefits and relatively low side effects, natural products such as food/die tary supplements, 
nutraceuticals and herbal medicines have been gaining popularity all over the world  The gap between the popularity of these remedies and the 
frequently weak scientific basis of their use is striking. In reality, the efficacy and true frequency of side effects for most herbal medicine 
products is not known because the majority have not yet been tested in large clinical trials and because pharmacovigilance systems are much 
less extensive than those in place for pharmaceutical products. In contrast to the popularity of herbal medicinal products, p hysicians and 
consumers often have a very critical view of robust efficacy and safety profiles. Application of pharmaceutical nanotechnology for plant actives 
and extracts, is gaining a tremendous growth and interest among the scientist. 
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INTRODUCTION 
Herbal medicinal products are pharmaceutical products of 
plant origin, also known as phyto-pharmaceuticals. They 
exclusively contain one or more herbal substances or herbal 
preparations as active ingredients or combinations of them 
(1). In contrast to synthetic drugs containing chemically 
active substances, they consist of a plethora of natural 
compounds that activate or modulate various target systems 
in an organism. Herbal medicinal products can be variable in 
their composition. Therefore, to obtain consistent efficacy 
and safety, standardised medicinal plant extracts are being 
used.  Evidence-based phytotherapy makes use of 
scientifically verified efficacy and safety by randomized 
controlled clinical trials. In general, herbal medicinal 
products are better tolerated and provide a superior benefit-
risk ratio to synthetic drugs. Therefore, evidence-based 
phyto-pharmaceuticals increasingly mentioned in clinical 
practice guidelines are first-line therapy in various diseases 
and indications. 
The term phyto-pharmacon/phyto-pharmaceutical is 
derived from the Greek designations phytón for plant 
and phármakon for medicine. Basically, these are herbal 
remedies which are prepared from herbal substances like 
dried plant parts such as leaves, blossom, herb, bark, or the 
roots traditionally already known to cure undesired 
conditions or illnesses. Today, most herbal preparations are 
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extracts from herbal substances in optimized form with 
known extraction solvent, drug-extract ratios and processing 
steps finalized as pharmacologically active dry extract. 
Highest quality (GMP), clinically confirmed efficacy and best 
tolerability and safety of standardized or quantified 
medicinal plant extracts are key measures for a successful 
phytotherapy approach. Other than food supplements or 
botanicals phyto-pharmaceuticals have to follow comparable 
regulatory guidelines as conventional drugs. Therefore, a 
high level of scientific evidence supports their efficacy and 
safety. For example, the St. John’s wort extract Ze 117 shows 
comparable efficacy as the synthetic antidepressant drugs 
imipramine or fluoxetine (SSRI) in the treatment of 
depressive disorders (2, 3). St. John’s wort (Hypericum 
perforatum L.) extracts have been attested with the well-
established use status by the EMA (4) and have reached 
Level A evidence (5) of efficacy as they confirmed to be 
superior to placebo in patients with major depression. 
Further, they are similarly effective as standard 
antidepressants and have fewer side effects as concluded in a 
Cochrane meta-analysis (6). 
Importantly, evidence-based phyto-pharmaceuticals should 
be clearly separated from alternative or complementary 
therapeutic approaches such as homeopathy. 
Phyto-pharmaceuticals are complex mixtures 
Unlike synthetic drugs, which are single active chemical 
substances, phyto-pharmaceuticals contain complex 
mixtures of hundreds of natural components. Among them, 
several isolated lead substances are well-known to be 
pharmacologically active while others are still under 
scientific investigation. The efficacy of herbal medicinal 
products results from complex interactions the active 
components with molecular target structures, such as 
receptors, enzymes, and transport systems. Herbal medicine 
was also the origin of conventional academic medicine. Even 
today, about 70% of medicines contain active ingredients 
that were originally derived from natural substances. Many 
classical active components, such as the pain reliever 
morphine, the cardiac glycoside digoxin or the 
anticholinergic agent atropine originate from plants. Today, 
however, such isolated substances are no longer considered 
as phyto-pharmaceuticals as they are either produced by 
chemical synthesis or are isolated and purified to be used as 
single substances. 
Morphine 
 The extract as active principle 
Phyto-pharmaceuticals are natural products and like other 
natural products, such as coffee, wine or cocoa, their quality 
depends on many factors starting from the raw material. For 
example the plant variety, cultivation, climate, harvest time, 
drying process and further processing steps can all affect the 
quality of the final preparation. It is therefore obvious that 
active ingredients in two different teas made from the same 
plant type can be present in very different concentrations. 
Similarly, no coffee tastes the same as another, although they 
are all prepared from coffee beans. For this reason, 
increasing numbers of extracts are being manufactured, 
which are standardised or quantified with regard to 
important components. Such extracts therefore always 
contain defined amounts of these active ingredients. 
Likewise undesired substances; those that cause side-effects, 
can be removed. Extracts from different manufacturers can 
thus only be compared with each other to a limited extent. 
Various different dosage forms, such as film-coated tablets, 
drops, or ointments, can be manufactured from the extracts. 
 
 
Phyto-pharmaceuticals are not homeopathic products 
 
Phyto-pharmaceuticals contain pharmacologically active 
ingredients that interact with protein structures in the 
human body, the so-called drug targets. They are, therefore, 
substantially different to homoeopathic remedies, which are 
highly diluted so that little or nothing of the initial active 
ingredient is actually left. In contrast to phytotherapy, 
homeopathy has no solid scientific evidence and is 
considered an alternative, complementary therapy approach. 
The concept of homeopathic products is fundamentally 
contrary to that of modern medicinal products. 
Clinically proven phytotherapy 
The highest demands are made on clinically proven phyto-
pharmaceuticals. Their effect and safety have to be verified 
in randomized, double-blind, (placebo)-controlled clinical 
trials. They are developed and scientifically evaluated in the 
same way as conventional medicinal products. This is very 
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different to traditional phyto-pharmaceuticals, where the use 
is primarily based on experience, for example the 
administration of tannin-containing black teas for diarrhoea. 
 Typical examples of clinically proven phyto-
pharmaceuticals are: 
 John’s wort for the treatment of depressive moods (2-4, 
6) 
 Butterbur for the treatment of hay fever (7) 
 Gingko for the treatment of declining mental 
performance (8) 
 Black cohosh for the treatment of menopausal 
symptoms (9) 
 Hawthorn for the treatment of cardiac symptoms (10) 
 Valerian and hops for the treatment of sleep disorders 
(11) 
Good Tolerance 
In principle, phyto-pharmaceuticals show high tolerability 
and safety but can bear the same risks as other medicinal 
products. They can have contraindications, there is a risk of 
undesired side-effects and drug interactions are possible. 
However, in general phyto-pharmaceuticals are well 
tolerated and often have a lower risk potential than synthetic 
chemical medications. Phyto-pharmaceuticals have a broad 
therapeutic margin and thus work well for simple and 
chronic symptoms. Due to their high tolerability and rather 
low interaction potential, they are well suited for elder 
patients with multiple medications. 
Phytopharmaceuticals – fighting disease with 
natural substances 
Phytopharmaceuticals are herbal medicines whose efficacy is 
down to one or several plant substances or active 
ingredients. They have been used for treating diseases since 
time immemorial. This traditional knowledge is still the basis 
for many medicinal products made from plants or parts 
thereof. Herbal medicines have been produced in Baden-
Württemberg for many generations.(12) 
Plants produce an incredible variety of natural compounds. It 
is therefore not surprising that humans make use of this 
huge diversity. Historical sources show that the use of 
medicinal plants goes way back to the Bronze Age. Europe 
has a culture of using medicinal plants that starts with 
Hildegard von Bingen, continues with Friedrich Sertürner 
who was the first to isolate morphine in pure form and ends 
with the modern-day production of herbal medicines. 
Phytopharmaceuticals are made from secondary 
plant metabolites 
What determines whether plants are suitable as food and for 
use as remedies for humans and animals? All plants function 
with a so-called primary metabolism that produces and 
degrades amino acids, fats, carbohydrates and nucleotides. 
These synthesis pathways are therefore present in all plants 
and also quite similar between different plant families. The 
so-called secondary metabolism is connected to the primary 
one as it uses building blocks from the primary metabolism 
to produce a large number of specialised compounds. These 
are classified into a very small number of groups according 
to their biosynthetic origins and chemical structures.(13) 
Alkaloids’ and amines are formed from amino acids. Other 
secondary metabolites include polyketides, steroids and 
phenylpropanoids. Around 80,000 unique chemical 
structures have been isolated from secondary higher plant 
metabolites.1 Different plant families produce different 
secondary metabolites, which also vary considerably in their 
chemical structure, resulting in a huge number of closely 
related structures. Plants produce different secondary 
metabolites in different developmental phases. Secondary 
metabolites are important for communicating and 
interacting with other organisms and with the environment. 
Tomatoes are an excellent example for illustrating the effect 
of certain secondary metabolites as defense barriers. The 
glycoalkaloids tomatine and dehydrotomatine protect green 
tomatoes from being eaten by herbivores and from infection 
by fungi and lichens. They are gradually degraded as the 
tomatoes mature. Ripe tomatoes contain little or no tomatine 
and dehydrotomatine and are safe to eat. Some secondary 
plant metabolites are formed only when the plant is infested 
by microbial pathogens. These so-called phytoalexins have 
an antimicrobial effect.(12),(13) 
Active plant substances for treating congestive 
heart failure 
The example of tomatoes shows that active plant ingredients 
are not necessarily individual active ingredients, but a 
mixture of several. Only a few herbal ingredients are used for 
therapeutic applications without further processing. 
Digitoxin is one such compound. It is isolated in pure form 
from purple foxglove (Digitalis purpurea) and is effective as 
a cardiac glycoside for treating congestive heart failure. 
However, in the majority of cases natural compounds are 
used as models for chemically synthesized pharmaceutical 
substances: salicylic acid, which is produced by the plant 
Filipendula ulmaria (commonly known as meadowsweet), 
and a salicylic acid derivative, acetylsalicylic acid, which is 
produced by willows, have a long tradition of reducing pain 
and fever, but have been produced using chemical methods 
for over a century.(14) 
Globally, herbal medicine has been considered an important 
alternative to modern allopathic medicine. Although the 
herbal medicines are very popular in the society, only few 
medicinal herbs have been scientifically evaluated for their 
potential in medical treatment. In most countries, the herbal 
drugs are poorly regulated and are often neither registered 
nor controlled by the health authorities. The safety of herbal 
medicines remains a major concern. In the United States, the 
Food and Drug Administration (FDA) has estimated that over 
50,000 adverse events are caused by botanical and other 
dietary supplements.[15] In addition, for most herbal drugs, 
the efficacy is not proved and the quality is not assured. The 
World Health Organization’s (WHO) Traditional Medicine 
(TM) Strategy 2014–2023 focuses on promoting the safety, 
efficacy, and quality of TM by expanding the knowledge base 
and providing guidance on regulatory and quality assurance 
standards.[16] In 2012, 119 WHO member states were 
regulating herbal medicines.[16] 
 Herbal medicine products include herbs, herbal materials, 
herbal preparations, and finished herbal products that 
contain parts of plants, other plant materials, or 
combinations thereof as active ingredients.[17] Herbs 
include crude plant material, for example, leaves, flowers, 
fruit, seed, and stems. Herbal materials include, in addition to 
herbs, fresh juices, gums, fixed oils, essential oils, resins, and 
dry powders of herbs. Herbal preparations are the basis for 
finished herbal products and may include comminuted or 
powdered herbal materials, or extracts, tinctures, and fatty 
oils of herbal materials. Finished herbal products consist of 
herbal preparations made from one or more herbs. 
Bhusnure et al                                                                                              Journal of Drug Delivery & Therapeutics. 2019; 9(3-s):1046-1057 
ISSN: 2250-1177                                                                                  [1049]                                                                                    CODEN (USA): JDDTAO 
The regulatory scenario regarding herbal preparations 
varies from country to country.[18] 
 Same regulatory requirements for all products. 
 Same regulatory requirements for all products, with 
certain types of evidence not required for herbal 
medicines . 
 Exemption from all regulatory requirements for herbal 
medicines. 
 Exemption from all regulatory requirements for herbal 
medicines concerning registration or marketing 
authorization. 
 Herbal medicines subject to all regulatory 
requirements.  
 Herbal medicines subject to regulatory requirements 
concerning registration or marketing authorization. 
 In Europe, for the marketing approval,[19] the herbal 
preparations are classified in three categories as 
follows: 
 Traditional medicinal use provisions (“traditional use”) 
accepted on the basis of sufficient safety data and 
plausible efficacy. 
 Well-established medicinal use provisions (“well 
established use”) demonstrated with the provision of 
scientific literature establishing that the active 
substances of the medicinal products have been in well-
established medicinal use within the European Union 
for at least 10 years, with recognized efficacy and an 
acceptable level of safety a product can be classified 
under. 
 Safety and efficacy data from the company’s own 
development (“stand alone”) or a combination of own 
studies and bibliographic data (“mixed application”).
 
 
Figure 1: Standardization of phytopharmaceutical 
FDA Botanical Drug Development Guidance [20] describes 
appropriate development plans for botanical drugs to be 
submitted in new drug applications (NDAs) and specific 
recommendations on submitting investigational new drug 
applications (INDs). The term botanical means products that 
include plant materials, algae, macroscopic fungi, and 
combinations thereof. FDA guidance recommends that IND 
must contain sufficient information to demonstrate that the 
drug is safe for testing in humans and that the clinical 
protocol is properly designed for its intended objectives.  
In addition to general regulatory requirements for an NDA - 
nonclinical pharmacology/toxicology studies, clinical 
evidence of efficacy and safety - for botanical drugs there are 
special requirements to ensure safety and quality of 
botanicals [20] as follows: 
Description of product and documentation of prior 
human experience 
 Description of botanical raw materials used and known 
active constituents or chemical constituents 
 Prior human experience. 
 Quality control o Botanical raw materials o Botanical 
drug substance and drug product  
 Identity, chemical characterization, manufacturing 
processes, biological assay, specifications, stability, 
current good manufacturing practices, and 
environmental assessment 
 Evidence to ensure therapeutic consistency  
 Botanical raw material control 
 Quality control by chemical test(s) and manufacturing 
control 
 Biological assay 
 Clinical data: Dose-response data and multiple batch 
clinical data.  
 In Indian regulations, the major class of Ayurveda, 
Siddha, or Unani (ASU) drugs included are:[21] 
 a. Classical ASU drugs as mentioned in the authoritative 
books of ASU system drugs, which are manufactured and 
named in accordance with the formulations described in the 
authoritative texts. For this category, issue of license to 
manufacture is based on citation in authoritative books and 
published literature, unless the drug is meant for a new 
indication when proof of effectiveness is required. 
 b. Patent or proprietary medicine makes use of ingredients 
referred in the formulations of authoritative texts but with 
intellectual intervention, innovation, or invention to 
manufacture products different from the classical medicine. 
For this category issue of a license to manufacture requires 
proof of effectiveness, based on the pilot study as per 
relevant protocol for ASU drugs. 
In 2010, Department of Ayurveda, Unani, Siddha, and 
Homeopathy (AYUSH) introduced Rule 158(B) which made 
the requirement of proof of effectiveness for licensing of a 
patent or proprietary ASU medicine.[21] This was followed 
by the release of GCP guidelines[21] for voluntary use by the 
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researchers interested in taking up clinical trials using ASU 
medicine. 
In India, ASU drugs have been under the purview of 
Department of AYUSH. In contrast, 2015 regulatory 
requirements for phytopharmaceuticals are under the 
purview of the Central Drugs Standards Control 
Organization (CDSCO).[23] This gazette notification defines 
regulatory provisions for phytopharmaceuticals and 
regulatory submission requirements for scientific data on 
quality, safety, and efficacy to evaluate and permit marketing 
for an herbal drug on similar lines to synthetic, chemical 
moieties. 
 Phytopharmaceutical drug is defined as[22] purified and 
standardized fraction with defined minimum four bioactive 
or phytochemical compounds (qualitatively and 
quantitatively assessed) of an extract of a medicinal plant or 
its part, for internal or external use of human beings or 
animals for diagnosis, treatment, mitigation, or prevention of 
any disease or disorder but does not include administration 
by parenteral route.[22] 
In Schedule Y, the newly added Appendix I B describes data 
to be submitted along with the application to conduct 
clinical trial or import or manufacture of a 
phytopharmaceutical drug in the country.[22] The 
regulatory requirements for NDA for the 
phytopharmaceutical drug include standard requirements 
for a new drug-safety and pharmacological information, 
human studies, and confirmatory clinical trials. For 
phytopharmaceutical drug, there is a lot of stress on: 
 Available information on the plant, formulation and 
route of administration, dosages, therapeutic class for 
which it is indicated and the claims to be made for the 
phytopharmaceutical, and supportive information 
from published literature on safety and efficacy and 
human or clinical pharmacology information 
 Data generated on: 
 Identification, authentication, and source of the plant 
used for extraction and fractionation 
 Process for extraction and subsequent fractionation 
and purification 
 Formulation details of phytopharmaceutical drug 
 Manufacturing process of formulation o Stability data. 
The new phytopharmaceuticals regulation permits the 
development of the drug development using advanced 
techniques of solvent extraction, fractionation, potentiating 
steps, modern formulation development, etc.[23]  
After NDA approval from CDSCO, the marketing status of the 
new phytopharmaceutical drug would be like that of a new 
chemical entity-based drug.[23] The new regulation for 
phytopharmaceutical is in line with regulations in USA, 
China, and other countries involving scientific evaluation 
and data generation.[23] 
 This new regulation is expected to promote innovations and 
development of new drugs from botanicals in a scientific 
way and would help in the acceptance of the use of herbal 
products by modern medical profession. It would encourage 
research in phytopharmaceutical drug development for 
academia, researchers, and industry.  
 
Figure 2: Development of standardized phytopharmaceuticals. 
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In past year Dr. Tu Youyou won the Nobel Prize in medicine 
for her discovery of artemisinin isolated from Artemisia 
annua for malaria. Hope with the new phytopharmaceutical 
regulation, the Indian scientists would develop noble 
intentions to discover phytopharmaceutical drugs for unmet 
medical needs. 
 Important evidence-based phyto-pharmaceuticals should be 
clearly separated from alternative or complementary 
therapeutic approaches such as homeopathy. 
Approaches to pre-formulation R and D for 
phytopharmaceuticals emanating from herb based 
traditional Ayurvedic processes 
Ayurveda, known to have about 5000 years of history, is 
widely used in India and few other countries. A large part of 
the formulations used in Ayurveda have herbs/botanicals as 
ingredients, although some may be made with minerals, 
metals, and ingredients of animal origin. Ayurvedic 
formulations are currently industrially prepared into 
products adopting large-scale technologies that 
pharmaceutical or food industry uses. Ayurveda mentions a 
number of processes and dosage forms.[24]  
The types of information prescribed in Ayurveda inclulde an 
infusion or a decoction of the botanical using water as a 
medium/solvent, either as a liquid or as concentrated 
decoction Ayurveda also advocates the use of semi-solid 
mass (avaleha) or dried powder, along with many other 
processes described in the texts. Such processed material 
actually forms extracts which in traditional dosages are 
formulated as pills.                               
Selection of plant extract as shown below 
In certain cases, the infusion or decoction in water is 
prepared in a dilute solution of a specified herb or herbs 
instead of water alone, a process referred to as bhavana. 
Materials prepared for any botanical use such a process as 
prescribed in official texts of Ayurveda as listed in the First 
Schedule of the Drugs and Cosmetics Act, 1940 of India (or 
for that matter in TCM or other TM) will come with the 
known history of safe use (HOSU). 
Phytopharmaceuticals are in essence the same as a botanical 
drug in common parlance and it was the US FDA (United 
States Food and Drug Administration) that first issued 
“Guidance to Industry on Botanical Drugs” that paved the 
way for phytopharmaceuticals to get a status of drug and 
marketing authorization as a drug after review by FDA 
US.[25] The definition of the Botanical in this Guidance 
document differs with the definition of the 
phytopharmaceutical given above. 
 
 
Figure 3: Selection of herbs and the extra 
Table 1: Lists a comparison of traditionally processed botanical as per Ayurveda and pharmaceutically processed 
botanical extracts, adopting decoction process of herbs/botanicals as a case. 
Traditionally processed Pharmaceutically processed 
Single boiling & concentration Multiple boiling-st –Marc-2nd boil-Marc- 3rd   
Boil combined filtrates 
Herb to water =1.4/8/18 
Concentration –open pan to 1/4soft extract.  
Extractive say 35% 
 Herb to water=1:8 
Concentration –closed vessel/ 
Vacuum/falling film –extractive>35% 
Convert soft ext .to dry  powder –adsorption on inert 
material 
Convert soft to dry powder –spray drying with or without  inert 
materials/bulking agents 
Bhavana extration with /in swaras/ plant/kwatha 
etc. 
Not KNOWN AS PROCESS. but involve  washing marc with solvent and 
adding the washing . 
Drying  and grinding control on 
temperature/time/uniformity 
High temperature exposure for short time at spray draying/on 
grinding. 
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The Drugs Technical Advisory Board of Govt. of India under 
the Drugs and Cosmetics Regulations (DCAR) has in 
principle approved notification of provisions in the drugs 
and cosmetics rules for phytopharmaceuticals as drugs.[26] 
Drug development using phytopharmaceuticals that bases 
the leads in traditional knowledge through “Reverse 
Pharmacology” is gaining attention, and it offers an 
alternative and perhaps more quicker/economic strategy for 
drug development.[27]  
Traditionally processed as per Ayurveda 
One case is selected here for discussion from amongst the 
many dosage forms made with aqueous extracts in 
Ayurveda. Ayurvedic process of a herb/botanical as pure 
extract –swaras (fresh juice), phant(warm or hot water 
infusion), kwatha or kashayam (hot water decoctions) – 
involves normally a herb to water ratio of 1:4 or 8 or 16 
depending on the soft or hard nature of the plant part used. 
In general, the process describes an open pan treatment and 
concentration is normally prescribed[24] to one-fourth of 
the initial amount of water or till one gets a soft extract 
(ghana/satwa). In some cases, such kwathas or ghanaare 
also adsorbed on an inert material like starch, etc., to get a 
powder or it may be allowed to dry under sun for a number 
of days till it forms a powder. This process involves 
obviously long-time heating and drying, and the controls on 
this process may vary to some extent batch wise. The dried 
material is often either soft lumps or in many cases hard 
lumps which need grinding. 
Pharmaceutically processed 
Many industrial processors who manufacture an aqueous 
extract of botanicals adopt large-scale boiling with water, 
and the process is repeated for each herb three times by 
filtering the first extract and extracting the mark a second 
and third time. Most commonly, herb to water ratio is 1:8 
during each of the three extraction steps. Combined filtrates 
are concentrated where a vacuum evaporation technology is 
adopted including use of falling film evaporators. 
Conversion of soft extracts so obtained is generally achieved 
by spray drying where the extract is exposed to high 
temperature but for a short time during the spraying step 
and for not more than an hour during the drying in the cone 
of a spray dryer. If proper technology is adopted, no step of 
grinding may be required at the end of this spray-dried 
material. 
Characterizing the material 
Adequate scientific studies would be required with an initial 
step of knowing and documenting in detail all the steps, in 
both the above processes. While a material prepared as per 
Ayurvedic process briefly discussed above can be labeled as 
a HOSU material, it is important to generate scientific data 
on the pharmaceutically processed material of the same 
herb produced industrially as per process briefly described 
above. This is important as the phytopharmaceutical raw-
material produced by the pharmaceutical process needs to 
be similar in characteristics and composition to a HOSU 
material and such similarity or dissimilarity data would only 
lead to extrapolatability of the safety profile of the HOSU 
material to the phytopharmaceutical. This is the first step of 
R and D before the phytopharmaceutical can be taken up for 
further formulation development. 
For generation of data on the material from the above two 
processes, a simple conduction of the normal 
physicochemical parameters, thin-layer chromatographic 
profiles for comparison, High Performance Liquid 
Chromatography, HPLC analysis for either qualitative or 
quantitative data for analytical or biomarkers that normally 
are adopted by various pharmacopoeia may not be adequate. 
In these tests, stress is high on understanding the chemistry 
of processed material involving organic compounds. Many 
botanicals are known to contain minerals and inorganic 
compounds in traces to appreciable levels, and for certain 
pharmacological or therapeutic activities, inorganic 
compounds also play a great role. R and D studies need to go 
beyond organic chemistry alone. Process changes in the 
above two processes need to be carefully documented, and 
its impact on the nature of the material produced need to be 
studied. For example, heating at high temperature forms 4-
deoxy-11, 12-didehydroandrographolide in Andrographis 
paniculata, Nees [kalmegh] that has been reported to be toxic 
and some pharmacopeia have a test and a limit for the same 
in the quality specifications. [28] Bhavana process of 
extraction and the impact it does on the nature and quality 
of extract may be change of pH of the medium/solvent. Can 
constituents of the bhavana herb like “phytosterols if 
present provide solubalizing effects, or does it add to 
isotonicity of the medium?”, such possibilities have not been 
studied or reported. If such effects are indeed seen, then the 
pharmaceutically processed material may also need to adopt 
the same in industrial scale to be similar to HOSU material. 
Limiting the data generation to Thin Layer Chromatography 
(TLC) profiles or HPLC analytical data may be inadequate in 
many cases especially when the botanical processed has 
more compounds that are not chromophoric in nature to 
provide UV absorption maxima. Principal component 
analysis (PCA) involving a number of measurement 
techniques namely Infra red Spectra, Ultra Violet Spectra, 
Nuclear Magnetic Resonance (IR, UV, NMR) and Mass 
Spectra (MS) among others offer a great advantage to 
generate adequately large pool of data that enable to apply 
statistical analysis. Such an approach offers a high degree of 
ability to analyze and come to a fair degree of assessment of 
similarities and dissimilarities between the HOSU material 
and the phytopharmaceutical. In addition, conducting in 
vivo bioefficacy screening/test protocols involving small 
animals or organ tissue cultures or cell-line-based assays 
helps to generate biological efficacy comparison data. 
Characterizing through fingerprinting 
A good-quality fingerprint cans [29]: 
 Provide an objective link between historical data and a 
proposed new material 
 Give an assessment of 
 Lab to production scalability 
 Raw-material variability (seasonal and regional) 
 Extraction robustness 
 Sample stability. 
Techniques for fingerprint development and its 
analysis 
HPLC is widely available although for a molecule to be 
detected by UV it must have a chromophores. Evaporative 
light-scattering detection (ELSD) and mass spectrometry 
(MS) offer more universal detection methods, but 
availability and cost can be limiting. Chromatographic 
resolution is essential to include as many components as 
possible. With the exception of MS detection, little 
information on component identity can be obtained. Ultra 
Performance Liquid Chromatography (UPLC) is an emerging 
technique with excellent resolving power 
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Fourier Transfer Infra red Spectra (FT-IR) is quick, relatively 
cheap, and widely available. A spectrum can give some 
qualitative information on the general compound classes 
present along with limited quantitative information. FT-IR 
spectra can be difficult to reproduce and are low resolution, 
which can result in small changes being missed. 
1H-NMR has the potential to detect any molecule containing 
hydrogen, thus making it highly universal. High-resolution 
instruments(>500 MHz) have sufficient sensitivity and 
resolution to give quality fingerprints for complex natural 
products. The spectra are qualitatively and quantitatively 
information rich, but the technique is expensive and not 
widely available. 
Analysis of fingerprints using principal component analysis 
Analytical results from multiple techniques can be combined 
to create a holistic fingerprint prior to input into a PCA 
model. PCA modeling improves with increased sample 
numbers. By identifying the techniques and subsequently 
the data points responsible for the variance, these 
components can be targeted for identification or monitored 
as part of a specification. 
Pre-formulation R and D 
Once having established the similarities of the 
phytopharmaceutical to the HOSU material, the pre-
formulation development work begins. Unlike pre-
formulation studies in a pharmaceutical based on synthetic 
drugs where large guidance and techniques are available, 
the area for phytopharmaceutical is bereft of the same. 
Knowledge on such studies seems to be residing in industry 
due to obvious reasons of confidentiality of such strategy. 
Creative adoption of many measurement techniques is 
needed to study the properties of the phytopharmaceuticals, 
so as to know the ability to obtain quality solid dosage form 
formulations. 
Some examples of the common attributes that need to be 
studied and suggestions are listed below, although these are 
non-exhaustive. For other tests/protocols, reference to the 
various editions of Ayurvedic Pharmacopoeia of India[24] is 
recommended. 
Solubility and re-solubility/re-dispersability: The 
pharmaceutically processed powder (referred as powder in 
the paras below for brevity) materials would have 
undergone some changes physically that render them not 
easy to dissolve or re-dissolve if needed for making syrup. 
Generally, the authors have experienced dissolution of about 
90-95% of the powder in water even with some warming. 
Knowledge of the extent of solubility is important to decide 
the need for additional steps of “adjustment to get the right 
quantum or, need for a step of filtration during 
manufacture.” 
Hygroscopicity: Most herbal extracts exhibit a fair degree of 
hygroscopicity although the opposite phenomenon 
“efflorescence” is not uncommon. Hygroscopicity 
information and extent of the same are very important in 
formulation of solid dosage forms, as it will have serious 
implications of the manufacture steps, environmental 
controls on the manufacturing, design of packs and 
packaging, and most importantly on the stability and 
microbial qualities of the material and formulations. 
A creative method for such a study would be to expose 
weighed quantities of the powders whose initial moisture 
contents are determined, in open Petri dishes to high 
humidity atmosphere. Samples from these Petri dishes can 
be drawn at frequent intervals and tested for moisture 
content and this testing can be continued till one reaches the 
“critical moisture content (CMC)” for that powder. CMC is 
that level of moisture when the powder starts to show 
changes in color/odor/nature (become cohesive, pulpy). 
Some extracts may show opposite tendencies-lose 
water/volatile materials. In such cases, the same testing will 
provide information on the weight loss rather than weight 
gains of a hygroscopic powder. 
One also needs to know what happens when moisture is 
absorbed does the material swell? Does the particle size 
enlarge/ grow? Observing samples of the powder-initial 
sample and that which has reached CMC under a microscope 
can provide good information. 
Swelling index: Many phytopharmaceuticals exhibit 
swelling properties and such a behavior will have impact in 
the steps involving granulation, or even after the powders 
are filled in capsules or compressed to get tablets. Swelling 
of the contents of the dosage forms can lead to serious 
quality problems including breaking of tablets, de-shaping of 
capsules, change in bulkiness color, etc., of granules. 
Swelling property is easily testable adopting Pharmacopeial 
method [30] given in monograph of for Isabgol (psyllium 
husk). 
Binding properties: Phytopharmaceutical produced by 
spray drying process often show varying ability to bind. The 
powders may vary from amorphous, fine to granular 
powders; vary from cohesive powders to free flowing 
powders, with low or high inherent binding capacities. 
Knowledge of the same is extremely important and 
measurement of bulk density –untapped/tapped can provide 
some information. Large difference indicates more air/intra-
particle voids. Powders with such large voids may show 
both, good inherent binding property or sometimes exactly 
the opposite. An experienced scientist can gauge the binding 
ability by just pressing some powder between fingers. 
Crystalinity and size, amorphous/crystalline: Powders may 
appear to be crystalline or amorphous to the naked eye. Not 
much information is available on this property and its 
impact on both pharmaceutical properties and 
pharmacological/therapeutic activity. Simple viewing under 
polarization microscopy or in specific cases, testing by 
powder X-ray diffraction is suggested. Determination of 
particle size distribution by normal methods of sieve 
analysis is suggested. 
Interaction with Excipients: 
 By an amendment to DCAR-Rule169, use of Permitted 
Excipients has been notified to assist in formulations of 
Ayurvedic dosage forms.[31] Selection of Excipients follow 
the normal dictum of compatibility with the powder. They 
should aid in improving the pharmaceutical properties like 
binding, lubricating, anti-sticking, anticaking, stabilizing, and 
solubilizing. The normal dictum that," the Excipients used 
should not interfere in the method of analysis" that is 
generally stated in the pharmacopoeia, needs a review in the 
context of phytopharmaceuticals as the type and nature of 
analysis done for phytopharmaceuticals is not the same as 
that which is done for a synthetic drug formulation. This 
applies greatly to the preservatives used with formulations 
involving a phytopharmaceutical. Also the recognition that 
all Excipients may not be necessarily “inert” is required. For 
example, in case of the phytopharmaceuticals formulated 
with magnesium oxide/magnesium carbonate as an 
anticaking agent, which may show slight “laxative effect or 
potentiate such effect if the phytopharmaceutical also is 
originally known for laxative effect.”(32) 
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These are but few examples of the area and more need to be 
studied to obtain the right 
 formulation with a phytopharmaceutical that mimics/is 
similar to the traditionally processed formulation, yet it is 
contemporary, pharmaceutically processed, and developed 
adopting industrial scale pharmaceutical technology. Greater 
funding for such research and development by the national 
and international agencies is the need of the hour apart from 
creating awareness of such research needs. (10)
 
 
Fig No 4: Herbal product as phytopharmaceutical: steps involved in the process of drug development. 
 
Plant-derived drugs launched (2000- 2010) 
Table 2: Plant-derived drugs launched (2000- 2010) 
Year Trade 
name 
Lead Compound Disease area Class 
2000 Arfadin Artemisinin Antimalarial 
Sesquiterpene lactone; Semi-
synthetic NP 
2002 Reminyl Leptospermone antityrosinaemia NP-derived 
2002 Apokyn Galantamine Alzheimer's disease Alkaloid; NP 
2004 Spiriva Morphine Parkinson's disease Alkaloid; semi-synthetic NP 
2005 Sativex Atropine Chronic obstructive pulmonary disease Alkaloid; semi-synthetic NP 
2007 Vyvanse Dronabinol/ Cannabidol Pain Cannabinoids; NP 
2008 Relistor Amphetamine Attention deficit hyperactivity disorder Amine; NP-derived 
2009 Qutenza Capsaicin Pain Vaniloid; NP 
2013 Crofelemer Oligomeric proanthocyanidin Antidiarrheal Agents Polyphenolic; NP 
 
Regulatory Challenges in Herbal Product 
Registration 
Regulatory Challenges  
• Standardization of Products 
• Collection strategy   
• Controls on adulterants  
• Reproducibility  
• Safety & Efficacy 
Standardization of Products 
 Herbs are natural products and chemical composition varies 
depending upon factors:  
• Botanical species.  
• Used chemotypes.  
• Anatomical part used (seed, flower. Root, leaf etc).  
• Storage: Sun, humidity, type of ground time of harvest.  
• Concentration of active principle or Biomarker.  
• Ascertain consistent chemical profile and biological 
activity.  
Need validation of above as part of regulatory process as 
lack of information about composition can turn to be black 
box for the herbal based treatment. 
Collection Strategy  
It is observed that concentration of bio-marker and active 
principal varies due to:  
• Weather conditions. 
• Soil quality. 
• Ground water and Moisture content.  
• Season etc.  
To ensure consistent quality product:   
• Need selection and validation of Collection strategy from 
wild or Good validated harvesting practices.  
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• Need good manufacturing practices for extraction modes 
and relate Control on Adulterants  Regulatory approval 
require to ascertain control of adulterants which can be 
found in the herbal material through different sources:  
• Pesticide residue (more likely if it is harvested in the 
agricultural fields)  
• Aflatoxin content  
• Bacterial/fungal growth  
• Heavy metal contamination The control need to be 
demonstrated from collection through different processing 
including extraction and final product manufacturing d 
parameters. 
Reproducibility  
 One of the biggest challenges due to variation in chemical 
profile due to various factors which can lead to possible 
variation in biological activity:  
• Must to identify and characterize the bio-marker or active 
principal (constituent). 
• Repetitive testing different batches to control batch to 
batch variation.  
• Establish the relation of active marker or constituent 
through pre-clinical and clinical studies.  
• Standardize collection strategy and validate the process to 
reduce the variability.  
• Develop appropriate analytical method to analyze the bio-
marker or active principal. 
 Processing of extract or Phytopharmaceutical  (if used 
as an extract) 
  Extraction methods, physico-chemical tests, microbial 
loads, heavy metal contaminants, chromatographic 
finger print profile with phytochemical reference 
markers, assay for active constituents or characteristic 
markers, if active constituents are not known.  
 Data on the active Phytopharmaceutical establishing 
the natural window of constituents (marker 
compounds) reflecting geographical and seasonal 
changes in a year, wherever applicable.  
 Information on any excipients (diluents or builders or 
stabilizers or preservatives used, if any) and their 
proportions.  
 Details of packaging of the extract or 
Phytopharmaceutical, storage conditions and labeling. 
• Formulation of Phytopharmaceutical drug applied 
for: 
  Composition, dosage, excipients, stabilizers, agents 
used, packaging materials, test(s) for the identification 
for the Phytopharmaceutical.  
 Quality specifications for actives and inactive 
Phytopharmaceutical, chromatographic finger print 
profile with phytochemical reference maker(s) and 
assay for active constituent(s) or characteristic 
maker(s), if active constituents are not known.  
• Manufacturing process of formulation  
• Stability data : for 0, 1, 2, 3 and 6 months 
• Safety and pharmacological information 
Provide comparative chemical and chromatographic profile, 
and spectroscopic information 
Safety and Efficacy  
• There is very limited scientific evidence to establish the 
safety and efficacy of the herbal products.  
• Out of top herbal products which have scientific evidence 
of efficacy has some concern over safety.  
• More advance technologies need to be used to characterize 
the herbal products to control the variance and establish the 
safety and efficacy.  
• Regulatory need more scientific / evidence based medicine 
which are designed through pre-clinical and clinical trial 
studies instead of tradition or supposed millenarian belief.  
• Need more funding for research and understanding of 
herbal products to meet regulatory requirements.  
• Current regulation of standard medical therapies can not 
be applied to herbal products, may need regulation which is 
suitable to herbal products. 
• Animal toxicity and safety data : 
  28 to 90 days repeat dose oral toxicity on two species 
of animals of which one should be non rodent as per 
Schedule Y;  
 In-vitro Genotoxicity data (Ame’s test and 
Chromosomal aberration test as per Schedule Y);  
 Dermal toxicity tests for topical use products;  
 Teratogenicity study (only if Phytopharmaceutical (s) 
is intended for usage during pregnancy). 
Pharmacological Activities of Phytomedicines: A 
Challenge Horizon for Rational Knowledge 
On a global perspective, we are yet in need of a rational, 
complete, and widely accepted theory to explain 
phytotherapy efﬁcacy and the mechanisms of action 
inherbaldrugs. Forthispurpose,anewapproachbasedonthe“-
omics”couldproveextremelyuseful. 
The “Modern Medicine Approach” Was Not Enough  
         A great number of herbs have been analyzed under the 
approach described previously, and a compound or group of 
compounds have been proposed as the biologically active 
agents that play the key role in the pharmacological effect 
[32]. Sometimes, this approach has resulted in the ability to 
discover compounds with great selectivity for a chosen 
target [33],which can be as diverse  as enzymes, receptors, 
antibodies, or signal cascades, but generally, herbal extracts 
are a mixture of bioactive or inactive compounds, and it has 
been suggested that the biological activity of herbal 
medicine results from the combination of different active 
components [34]. Systems biology has revealed that human 
cells and tissues are composed of complex, networked 
systems with redundant, convergent, and divergent 
signaling pathways, with different possibilities of inter 
action when such agreat number of compounds converge 
[33]. The combination of effects is described with the terms 
add it,synergy, and antagonism, although both synergy and 
antagonism can be deﬁned in relation to an additive 
expectation. Strictly speaking, synergism, which was 
advanced in a landmark paper by Williamson [35] and 
further outlined by Ulrich-Merzenich et al. [36], is deﬁned by 
a combined effect of substances that is greater than would 
be expected from the individual contributions [37]. Sarris et 
al. [38] deﬁned it as a “super-additive” biological effect when 
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combined, as opposed to being just the sum of their 
individual parts or additivity (e.g., 1 + 1 = 5, not 2). 
Antagonism, or “negative synergy”, on the contrary, appear 
sifit works backward sandared effect is achieved.. According 
to investigations carried out by Einbond et al. [39], the 
inhibitory effect on Na+-K+-ATPase activity, compared with 
the summation effect obtained by each one administered 
alone, is higher when co-administered. In this case, this 
observation is an example of pharmacodynamic synergy 
because actein or digitoxin facilitates the action of the other 
in the same target. Synergy can also be related to 
pharmacokinetic parameters. For example, permeability 
values and the absorption rate of some drugs can be altered. 
Coumarins can increase the active absorption via carrier-
mediated proteins (i.e., of ﬂavonoids) and inhibit P-gp-
mediated efﬂux systems .That is exactly what happens in a 
plant extract. The ingredients with little or no direct activity 
on the pathogenic process may assist the “actives” to reach 
the target, either by improving bioavailability or decreasing 
the metabolism and excretion of the active principle [41], 
and in the overall pharmacological effects and the 
therapeutic efﬁcacy of multi-extract preparations, 
constituents are involved synergistically [42]. In the same 
sense, the complex matrix in a plant can also exhort 
protection of the active principles, through antioxidative and 
other protection actions [43]. The expected overall effect is 
not easy topredict based on the known effects of the 
different substances in an individual herbal preparation 
assuming that each component acts on different 
pharmacological targets. In the case previously described 
(actein/digitoxin), not only does Na+-K+-ATPase activity 
increase, but the expression of NF-κB promoters, p-ERK, p-
Akt, and cyclin D1 protein levels are also affected.  
 The treatment of diseases with mono-substance therapy, 
“the silver bullet concept”, in other words, with a 
characterized compound and a perfectly deﬁned mechanism 
of action at a particular dose that fulﬁlls the positive 
(efﬁcacy/stability) and negative requirements (such as 
toxicity) has been inherited from classical pharmacology and 
assumed by phytotherapy in an attempt to achieve 
rationality. However, especially in the treatment of chronic 
diseases, it is increasingly viewed as inadequate in many 
clinical situations due to ineffectiveness, resistance 
problems, and the side effects that may occur [44]. For these 
reasons, the herbal medicinal preparation derived from 
several herbal plants that contains a large number of 
secondary phytochemical compounds has been seen as 
feasible for chronic therapies. The rationale behind 
combinations is frequently questioned, and it remains 
challenging to assess the individual contribution of each of 
the combination partners to the over all activity of the 
preparation[44,45].   
The “-Omic” Technologies; Present and Future Epigenetic 
studies are already demonstrating that combinations of 
constituents do not only have the added effect of triggering 
an increase in the number of expressed genes; they do in fact 
trigger new genes altogether [38]. The mechanism 
underlying phytotherapy efﬁcacy is, clearly, much more 
sophisticated. A good example of this can be found in the 
work of Ulrich-Merzenich et al. [36], who showed a 
summary map of genes expressed in human chondrocytes 
stimulated with willow bark extract STW-33-1 (30 µg/mL 
and 50 µg/mL) as well as with quercetin (10 µM), diclofenac 
(30 µg/mL), and acetylsalicyclic acid (50 µg/mL). 
Undoubtedly, the results demonstrated that each of the 
substances and extracts, in spite of the fact that all exert 
anti-inﬂammatory activity, has a speciﬁc gene expression 
proﬁle, as well as that they will ow bark extract showed a 
different gene expression proﬁle depending on the dose 
administered. To study this further, a similar map of genes 
expressed in the blood cells of rats after the animals were 
treated with willow bark extract STW-33-1 and its different 
fractions (ethanol, ethyl acetate, and water) was 
constructed. In this case, as might be expected, the treatment 
with different fractions of the extract leads to distinct gene 
expression proﬁles in vivo as a direct consequence of the 
different combinations of compounds and their 
concentration in each fraction. To sum up, it must be 
concluded that not only is the pattern of gene expression 
(signature in some texts) different depending on whether a 
substance or a mixture of substances (extract) is 
administered, presumably more complex in the last case, but 
also depending on the substance/extract concentration or 
the extract fraction administered 
The development and reﬁnement of “-omic” technologies, 
including genomics/transcriptomics, proteomics, and 
metabolomics, has led to advances in the assessment of both 
the efﬁcacy and, no less important, safety of herbal 
medicines [49,50] referred to by some authors as 
“herbomics”, although this term is still in its infancy. An 
interesting study is the one published by Wang et al. [50], in 
which the possible toxicological role of Matricaria 
chamomilla was evaluated using metabolomics approaches. 
After tea administration in human volunteers (200 mL/day 
for 2 weeks, made from fresh ﬂowers), urine was analyzed 
during the dosing period and two weeks later. Its 
administration results in an increase in the excretion of 
some metabolites (including glycine and hippurate), while 
creatinine excretion decreased, with baseline parameters 
still altered 14 days later. Apart from the therapeutic effect,it 
is clear that Matricaria chamomillatea modiﬁed 
patients’homeostasis. On that basis, the authors suggest that 
gut microﬂora might have been disrupted. Security 
assessment must include the kinds of techniques able to 
fulﬁll differences between the toxicology of a speciﬁc 
compound and that of whole herbs or an extract. Despite the 
high level of complexity and cost of “-omic” techniques, they 
are the only way the pharmacological action of many species 
can be fully understood. They are the key to a rational and 
fully accepted form of phytotherapy 
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